Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5567-5569

  Dutta, Noton K ^a   Pinn, Michael L ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; THIORIDAZINE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL CLEARANCE; DRUG ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; LUNG; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; THIORIDAZINE; TUBERCULOSIS, PULMONARY;

EID: 84906076108     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03408-14     Document Type: Article

References (21)

1. Sarathy JP, Dartois V, Lee EJ. 2012. The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance. Pharmaceuticals 5:1210-1235. http://dx.doi.org/10.3390/ph5111210.
2. Almeida Da Silva PE, Palomino JC. 2011. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66:1417-1430. http://dx.doi.org/10.1093/jac/dkr173.
3. Amaral L, Kristiansen JE, Abebe LS, Millett W. 1996. Inhibition of the respiration of multidrug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 38:1049-1053. http://dx.doi.org/10.1093/jac/38.6.1049. (Pubitemid 27073284)
4. van Ingen J, van der Laan T, Amaral L, Dekhuijzen R, Boeree MJ, van Soolingen D. 2009. In vitro activity of thioridazine against mycobacteria. Int. J. Antimicrob. Agents 34:190-191. http://dx.doi.org/10.1016/j.ijantimicag.2009. 02.015.
5. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917-922. http://dx.doi.org/10.1128/AAC.47.3. 917-922.2003. (Pubitemid 36254216)
6. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. 2007. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21:771-775.
7. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J, Boeree MJ. 2010. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 5:e12640. http://dx.doi.org/10.1371/journal.pone.0012640.
8. Abbate E, Vescovo M, Natiello M, Cufre M, Garcia A, Gonzalez Montaner P, Ambroggi M, Ritacco V, van Soolingen D. 2012. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J. Antimicrob. Chemother. 67:473-477. http://dx.doi.org/10.1093/jac/dkr500.
9. Dutta NK, Pinn ML, Karakousis PC. 2014. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Antimicrob. Agents Chemother. 58:4048-4053. http://dx.doi.org/10. 1128/AAC.02981-14.
10. Dutta NK, Mehra S, Kaushal D. 2010. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising antimycobacterial thioridazine. PLoS One 5:e10069. http://dx.doi.org/10.1371/ journal.pone.0010069.
11. Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. 2011. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Recent Pat. Antiinfect. Drug Discov. 6:128-138. http://dx.doi.org/10.2174/157489111796064597.
12. Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD. 2014. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58:2491-2503. http://dx.doi.org/10.1128/AAC.02293-13.
13. Dutta NK, Illei PB, Jain SK, Karakousis PC. 9 May 2014. Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice. Am. J. Pathol. http://dx.doi.org/10.1016/j.ajpath.2014.03. 008.
14. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36:548-551. http://dx.doi.org/10.1128/AAC.36.3.548.
15. Dhillon J, Dickinson JM, Sole K, Mitchison DA. 1996. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob. Agents Chemother. 40:552-555. (Pubitemid 26076566)
16. Udwadia ZF, Sen T, Pinto LM. 2011. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat. Antiinfect. Drug Discov. 6:88-91. http://dx.doi.org/10.2174/157489111796064614.
17. Viveiros M, Amaral L. 2001. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 17:225-228. http://dx.doi.org/10.1016/S0924-8579(00)00343-5. (Pubitemid 32229901)
18. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, Meek C, Leff R, Pasipanodya J, Gumbo T. 2013. Thioridazine pharmacokinetic-pharmacodynamic parameters "wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob. Agents Chemother. 57:5870-5877. http://dx.doi.org/10.1128/AAC.00829-13.
19. Sohaskey CD. 2008. Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J. Bacteriol. 190:2981-2986. http://dx.doi.org/10.1128/JB.01857-07. (Pubitemid 351508198)
20. Dutta NK, Pinn ML, Zhao M, Rudek MA, Karakousis PC. 2013. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. J. Antimicrob. Chemother. 68:1327-1330. http://dx.doi.org/10.1093/jac/dkt037.
21. Sohaskey C. 2011. Latent tuberculosis: is there a role for thioridazine? Pat. Antiinfect. Drug Discov. 6:139-146. http://dx.doi.org/10.2174/ 157489111796064551.